Parkinson’s disease (PD) has been traditionally characterized by the motor symptoms of disease such as tremor, altered gait, and bradykinesia, with a well-established pathophysiology related to loss of dopaminergic neurons in substantia nigra. Nevertheless, the large variability in presentation and progression of disease, and a constellation of additional non-motor symptoms related to the disease make diagnosis and management of PD dependent on expert clinical assessment and patient report. In the absence of a quantifiable laboratory or imaging biomarker, the goal of precision medicine as applied to PD will be impossible to achieve. Despite the efforts of engineers and physicians over the past 90 years to build mechanical and electronic devices to assess the severity (and change) of symptoms such as tremor, these objective measurements fail to capture the complexity of disease as they collect a single time-point measurement of a single sign. In this chronic and progressive illness, assessing function (such as with activities of daily living) is also of great importance, and the efforts to include these in common rating scales such as the UPDRS provide a brief episodic view into the lives of patients. Consequently, the complexity of the disease, and the variability between and within patients, cannot be captured with these simple evaluations.
No takes yet. Share an insight, caveat, or question.
Trister et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: